Cytochrome P450 isoenzymes and UDP-glucuronosyltransferase 1-1 (CYP and UGT1A1)

Cytochrome P450 (CYP) isoenzymes and UDP-glucuronosyltransferase 1-1 (UGT1A1) are the primary enzymatic systems responsible for the metabolism of the majority of clinical drugs and endogenous lipophilic compounds (UniProt, 2024). CYP enzymes, such as CYP3A4, CYP2D6, and CYP2C9, catalyze Phase I oxidative reactions, while UGT1A1 is a critical Phase II enzyme that catalyzes the glucuronidation of bilirubin and xenobiotics like the active metabolite of irinotecan, SN-38 (PubMed, 2022). Together, these enzymes determine the pharmacokinetic profile, systemic exposure, and clearance rates of therapeutic agents. Genetic polymorphisms in these enzymes, such as the UGT1A1*28 allele or various CYP2D6 variants, significantly contribute to inter-individual variability in drug efficacy and the risk of adverse drug reactions (PharmGKB, 2023). Understanding the interplay between these enzymes is essential for predicting drug-drug interactions and implementing precision medicine through pharmacogenomic testing (FDA, 2020). These enzymes are often considered 'anti-targets' or 'metabolic targets' in drug development, where their inhibition or induction can lead to significant safety concerns or altered drug performance.

Other names

Phase I and Phase II drug-metabolizing enzymesCYP450 and UGT1A1Xenobiotic-metabolizing enzymesMicrosomal enzymes

These enzymes facilitate the biotransformation of drugs through Phase I oxidative reactions (CYPs) and Phase II glucuronidation (UGT1A1), converting lipophilic compounds into water-soluble metabolites for biliary or renal excretion (StatPearls, 2023).